DOCSLIB.ORG

Acute Pain Management in Trauma Patients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acute Pain Management in Trauma Patients ACS TRAUMA QUALITY PROGRAMS BEST PRACTICES GUIDELINES FOR ACUTE PAIN MANAGEMENT IN TRAUMA PATIENTS Supported by the American Society of Anesthesiologists (ASA) Administrative Council* Released November 2020 Table of Contents Introduction .............................................................................................................................................. 4 Pain Physiology ........................................................................................................................................ 6 Pain Assessment ....................................................................................................................................10 Unidimensional Assessment Tools for Cognitively Intact Adults ............................ 11 Assessment Tools for Adult Patients with Cognitive Impairment ..........................12 Functional Pain Assessment Tools ......................................................................................14 Pain Assessment in Older Adults .........................................................................................16 Pediatric Pain Assessment Tools ..........................................................................................16 Pain Reassessment ...................................................................................................................18 Nonpharmacologic Pain Management .........................................................................................21 Cognitive Strategies .................................................................................................................22 Physical Strategies ....................................................................................................................25 Pharmacologic Analgesia ...................................................................................................................31 Acetaminophen .........................................................................................................................32 N-methyl-D-aspartate (NMDA) Antagonists ...................................................................35 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) ..........................................................36 Opioids..........................................................................................................................................36 Adjuvant Analgesics.................................................................................................................38 Regional Analgesia ..............................................................................................................................43 Neuraxial Techniques: Epidural and Paravertebral Blocks .........................................44 Ultrasound-Guided Fascial Plane Blocks ..........................................................................45 Extremity Blocks: Brachial Plexus, Femoral, and Sciatic ..............................................49 Local Anesthetic Systemic Toxicity ....................................................................................49 Multimodal Pain Management ........................................................................................................52 Pain Management in the Prehospital Setting ............................................................................58 Pain Management in the Emergency Department ..................................................................61 Pain Management in Perioperative Care .....................................................................................64 Preoperative Care .....................................................................................................................65 Intraoperative Care ...................................................................................................................65 Pain Management in the Intensive Care Unit .............................................................................68 Pharmacologic Analgesia ......................................................................................................70 2 Transition Out of Intensive Care...........................................................................................71 Pain Management at Hospital Discharge ....................................................................................74 Assessment Considerations ..................................................................................................75 Considerations for Pharmacologic Analgesics ...............................................................76 Pain Management in Older Adults .................................................................................................81 Medications in the Aging Population ................................................................................82 Pain Management in Children .........................................................................................................86 Nonpharmacologic Pain Management .............................................................................87 Pharmacologic Analgesia .......................................................................................................88 Regional Analgesia ...................................................................................................................88 Pain Management in Pregnant Patients ......................................................................................93 Nonpharmacologic Pain Management .............................................................................94 Pharmacologic Analgesia .......................................................................................................94 Pain Management in Patients with Depression ........................................................................98 Pain Management in Patients on Chronic Opioid Therapy or with Opioid Use Disorder ..........................................................................................................................................101 Impact on Patient Outcomes ..............................................................................................102 Assessment Considerations ...............................................................................................103 Management of Patients on Prescribed Opioid Therapy for Chronic Pain ........103 Management of Patients with Untreated OUD ............................................................103 Management of Patients Receiving Treatment for OUD ......................................... 104 Coordination with Chronic Pain or Primary Care Provider .......................................105 Pain Management at End-of-Life ..................................................................................................107 Principles of Medication Management .......................................................................... 108 Drugs and Dosages ............................................................................................................... 109 Implementing the Best Practices Guideline for Acute Pain Management in Trauma Patients ..............................................................................................................................110 Recommended Trauma Performance Improvement Guideline Integration ................114 Acronyms ...............................................................................................................................................117 Appendix A: Doloplus-2 Scale.........................................................................................................118 Expert Panel ..........................................................................................................................................119 3 function in geriatric and pregnant INTRODUCTION patients; and pain management goals can change drastically at end-of-life. The majority of trauma victims experience pain.1 Acute pain can Pain management changed over the last impact respiratory function, increase decade, in large part due to the opioid metabolic demand, impair wound crisis in the United States. The scope healing, suppress immunity, and of the opioid crisis—and the impact of reduce mobility. Inadequate acute prescription drugs—resulted in a call pain management after trauma delays from the American Medical Association return to work, lowers quality of life, and (AMA), the Orthopaedic Trauma increases post-traumatic stress disorder Association (OTA), and the American (PTSD) risk.2 Poorly managed acute College of Surgeons (ACS), among others, 4,5,6 pain also increases the risk of chronic to minimize opioid use. New research pain development. Nearly two-thirds supporting the safety and efficacy of of patients report at least moderate nonopioid analgesia drives innovative pain 12 months after injury, and three practices within trauma centers across in four report pain interference with the country, pushing providers and activities of daily living, such as social programs to deliver better care. engagement, work, and cognitive and This publication is intended to provide 3 emotional function. Pain is associated an evidence-based, practical guide with decreased self-efficacy and to acute pain management of the increased risk of depression. This effect trauma patient. It begins with an may be more pronounced after trauma, overview of pain physiology, pain because traumatic events cause distress assessment,
Load more

Recommended publications
  • Study Protocol and Statistical Analysis Plan
    The University of Texas Southwestern Medical Center at Dallas Institutional Review Board PROJECT SUMMARY Study Title: Ultrasound-guided fascia iliaca compartment block versus periarticular infiltration for pain management after total hip arthroplasty: a randomized controlled trial Principal Investigator: Irina Gasanova, MD Sponsor/Funding Source: Department of Anesthesiology and Pain Management, UT Southwestern Medical School IRB Number: STU 122015-022 NCT Number: NCT02658240 Date of Document: 01 April 2016 Page 1 of 7 Purpose: In this randomized, controlled, observer-blinded study we plan to evaluate ultrasound-guided fascia iliaca compartment block with ropivacaine and periarticular infiltration with ropivacaine for postoperative pain management after total hip arthroplasty (THA). Background: Despite substantial advances in our understanding of the pathophysiology of pain and availability of newer analgesic techniques, postoperative pain is not always effectively treated (1). Optimal pain management technique balances pain relief with concerns about safety and adverse effects associated with analgesic techniques. Currently, postoperative pain is commonly treated with systemic opioids, which are associated with numerous adverse effects including nausea and vomiting, dizziness, drowsiness, pruritus, urinary retention, and respiratory depression (2). Use of regional and local anesthesia has been shown to reduce opioid requirements and opioid-related side effects. Therefore, their use has been emphasized (3, 4, 5, 6). Fascia Iliaca compartment block (FICB) is a field block that blocks the nerves from the lumbar plexus supplying the thigh (i.e., lateral femoral cutaneous femoral and obturator nerves). The obturator nerve is sometimes involved in the FICB but probably plays little role in postoperative pain relief for most surgeries of the hip and proximal femur.
    [Show full text]
  • Changes in Birth-Related Pain Perception Impact Of
    Archives of Gynecology and Obstetrics https://doi.org/10.1007/s00404-017-4605-4 MATERNAL-FETAL MEDICINE Changes in birth‑related pain perception impact of neurobiological and psycho‑social factors Sebastian Berlit1 · Stefanie Lis2 · Katharina Häfner3 · Nikolaus Kleindienst3 · Ulf Baumgärtner4 · Rolf‑Detlef Treede4 · Marc Sütterlin1 · Christian Schmahl3,5 Received: 9 October 2017 / Accepted: 21 November 2017 © Springer-Verlag GmbH Germany, part of Springer Nature 2017 Abstract Purpose To analyse post-partum short- and long-term pain sensitivity and the infuence of endogenous pain inhibition as well as distinct psycho-social factors on birth-related pain. Methods Pain sensitivity was assessed in 91 primiparous women at three times: 2–6 weeks before, one to 3 days as well as ten to 14 weeks after childbirth. Application of a pressure algometer in combination with a cold pressor test was utilised for measurement of pain sensitivity and assessment of conditioned pain modulation (CPM). Selected psycho-social factors (anxiety, social support, history of abuse, chronic pain and fear of childbirth) were evaluated with standardised questionnaires and their efect on pain processing then analysed. Results Pressure pain threshold, cold pain threshold and cold pain tolerance increased signifcantly directly after birth (all p < 0.001). While cold pain parameters partly recovered on follow-up, pressure pain threshold remained increased above baseline (p < 0.001). These pain-modulating efects were not found for women with history of abuse. While CPM was not afected by birth, its extent correlated signifcantly (r = 0.367) with the drop in pain sensitivity following birth. Moreover, high trait anxiety predicted an attenuated reduction in pain sensitivity (r = 0.357), while there was no correlation with fear of childbirth, chronic pain and social support.
    [Show full text]
  • Substance P: Transmitter O. Nociception (Minireview)
    ENDOCRINE REGULATIONS, Vol. 34,195201, 2000 195 SUBSTANCE P: TRANSMITTER O NOCICEPTION (MINIREVIEW) M. ZUBRZYCKA1, A. JANECKA2 1Department of Physiology and 2Department of General Chemistry, Institute of Physiology and Biochemistry, Medical University of Lodz, Lindleya 3, 90-131 Lodz, Poland E-mail: [email protected] Substance P plays the role of a neurotransmitter immunoreactive fibers has also been detected in lam- and neuromodulator in the central and peripheral ina V of the dorsal horn (LJUNGDAHL et al. 1978), lam- nervous system. The presence of substance P in de- ina X surrounding the central canal (LAMOTTE and myelinated sensory fibres, as well as in the small SHAPIRO 1991), the nucleus dorsalis, interomediolat- and medium-sized neurons of spinal dorsal horn sub- eral cell column, and the ventral horn (PIORO et stantia gelatinosa gives a structural basis for the al.1984). Electric stimulation of the dorsal root, or hypothesis that SP plays an important role of peripheral nerve endings, causes a substantial release a mediator in the processing of nociceptive informa- of SP within the substantia gelatinosa of spinal dor- tion. In this paper recent advances on the effect of sal horns (OTSUKA and KANISHI 1976). SP on conduction and modulation of nociceptive In the dorsal regions of the spinal dorsal horn, impulsation are reviewed. The studies concerning the besides SP also large quantities of gamma-aminobu- role of SP in the prevertebral ganglia and spinal dor- tyric acid (GABA) are present, but reduction of sal horns has been presented, including the distribu- GABA levels has no effect on the SP content, and tion of SP in the spinal cord, as well as its pre- and similarly, reduction of SP levels does not cause any postsynaptic actions on excitatory and inhibitory decrease of GABA concentration in this region of postsynaptic potentials (EPSP and IPSP) and the ef- the spinal cord (TAKAHASHI and OTSUKA 1975).
    [Show full text]
  • Recognition and Alleviation of Distress in Laboratory Animals
    http://www.nap.edu/catalog/11931.html We ship printed books within 1 business day; personal PDFs are available immediately. Recognition and Alleviation of Distress in Laboratory Animals Committee on Recognition and Alleviation of Distress in Laboratory Animals, National Research Council ISBN: 0-309-10818-7, 132 pages, 6 x 9, (2008) This PDF is available from the National Academies Press at: http://www.nap.edu/catalog/11931.html Visit the National Academies Press online, the authoritative source for all books from the National Academy of Sciences, the National Academy of Engineering, the Institute of Medicine, and the National Research Council: x Download hundreds of free books in PDF x Read thousands of books online for free x Explore our innovative research tools – try the “Research Dashboard” now! x Sign up to be notified when new books are published x Purchase printed books and selected PDF files Thank you for downloading this PDF. If you have comments, questions or just want more information about the books published by the National Academies Press, you may contact our customer service department toll- free at 888-624-8373, visit us online, or send an email to [email protected]. This book plus thousands more are available at http://www.nap.edu. Copyright © National Academy of Sciences. All rights reserved. Unless otherwise indicated, all materials in this PDF File are copyrighted by the National Academy of Sciences. Distribution, posting, or copying is strictly prohibited without written permission of the National Academies Press. Request reprint permission for this book. Recognition and Alleviation of Distress in Laboratory Animals http://www.nap.edu/catalog/11931.html Recognition and Alleviation of Distress in Laboratory Animals Committee on Recognition and Alleviation of Distress in Laboratory Animals Institute for Laboratory Animal Research Division on Earth and Life Studies THE NATIONAL ACADEMIES PRESS Washington, D.C.
    [Show full text]
  • Nociceptors – Characteristics?
    Nociceptors – characteristics? • ? • ? • ? • ? • ? • ? Nociceptors - true/false No – pain is an experience NonociceptornotNoNo – –all nociceptors– TRPV1 nociceptorsC fibers somata is areexpressed may alsoin have • Nociceptors are pain fibers typically associated with Typically yes, but therelowsensorynociceptorsinhave manyisor ahigh efferentsemantic gangliadifferent thresholds and functions mayproblemnot cells, all befor • All C fibers are nociceptors nociceptoractivationsmallnociceptorsincluding or large non-neuronalactivation are in Cdiameter fibers tissue • Nociceptors have small diameter somata • All nociceptors express TRPV1 channels • Nociceptors have high thresholds for response • Nociceptors have only afferent (sensory) functions • Nociceptors encode stimuli into the noxious range Nociceptors – outline Why are nociceptors important? What’s a nociceptor? Nociceptor properties – somata, axons, content, etc. Nociceptors in skin, muscle, joints & viscera Mechanically-insensitive nociceptors (sleeping or silent) Microneurography Heterogeneity Why are nociceptors important? • Pain relief when remove afferent drive • Afferent is more accessible • With peripherally restricted intervention, can avoid many of the most deleterious side effects Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input …. Price DD, Craggs JG, Zhou Q, Verne GN, et al. Neuroimage 47:995-1001, 2009 IBS IBS rectal rectal placebo lidocaine rectal lidocaine Time (min) Importantly, areas of somatic referral were
    [Show full text]
  • Analgesic Policy
    AMG 4pp cvr print 09 8/4/10 12:21 AM Page 1 Mid-Western Regional Hospitals Complex St. Camillus and St. Ita’s Hospitals ANALGESIC POLICY First Edition Issued 2009 AMG 4pp cvr print 09 8/4/10 12:21 AM Page 2 Pain is what the patient says it is AMG-Ch1 P3005 3/11/09 3:55 PM Page 1 CONTENTS page INTRODUCTION 3 1. ANALGESIA AND ADULT ACUTE AND CHRONIC PAIN 4 2. ANALGESIA AND PAEDIATRIC PAIN 31 3. ANALGESIA AND CANCER PAIN 57 4. ANALGESIA IN THE ELDERLY 67 5. ANALGESIA AND RENAL FAILURE 69 6. ANALGESIA AND LIVER FAILURE 76 1 AMG-Ch1 P3005 3/11/09 3:55 PM Page 2 CONTACTS Professor Dominic Harmon (Pain Medicine Consultant), bleep 236, ext 2774. Pain Medicine Registrar contact ext 2591 for bleep number. CNS in Pain bleep 330 or 428. Palliative Care Medical Team *7569 (Milford Hospice). CNS in Palliative Care bleeps 168, 167, 254. Pharmacy ext 2337. 2 AMG-Ch1 P3005 3/11/09 3:55 PM Page 3 INTRODUCTION ANALGESIC POLICY ‘Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage’ [IASP Definition]. Tolerance to pain varies between individuals and can be affected by a number of factors. Factors that lower pain tolerance include insomnia, anxiety, fear, isolation, depression and boredom. Treatment of pain is dependent on its cause, type (musculoskeletal, visceral or neuropathic), duration (acute or chronic) and severity. Acute pain which is poorly managed initially can degenerate into chronic pain which is often more difficult to manage.
    [Show full text]
  • Ultrasound-Guided Fascia Iliaca Compartment Block (FICB)
    Ultrasound-Guided Fascia Iliaca Compartment Block (FICB) Hip Fracture Any of the following present? 1) Neurologic deficit 2) Multisystem Trauma 3) Allergy to local anesthetic Yes *Anticoagulated patients – physician No discretion Standard Care Procedure Details 1) Document distal neurovascular exam in EPIC 1) PO acetaminophen 2) Consult ortho (do not need to await callback) (1,000mg) 3) Obtain verbal consent from patient 2) Consider 0.1 mg/kg 4) Position Patient and U/S Machine morphine or opioid 5) Order Bupivacaine (dose dependent) a. Max 2 mg/kg equivalent b. i.e. 100 mg safe for 50 kg patient 3) Screening labs, CXR, 6) Standard ASA monitoring (telemetry during procedure with ECG, type and screen continuous pulse oximetry, BP measurement, and IV access) 7) Perform FICB 4) Consult orthopedics and medicine as 8) Inform patients on block characteristics: a. Onset ~ 20 minutes necessary b. Duration ~ 8-12 hours Equipment Required Counseling Ultrasound Machine 1) Linear/Vascular Probe set to “Nerve” Benefits setting for best results Decreases: Anesthetic: 1) Pain 1) 0.5% Bupivacaine (20-30 cc) 2) 1% Lidocaine (3-5 cc) 2) Delirium 3) Opioids Saline (10 cc) 4) Hypoxia Syringes: 1) 30 cc 2) 3-5 cc Risks Needles: 1) Pain at injection site 1) Blunt fill 2) Temporary nerve palsy 2) 25G 3) 18G LP needle 3) Intravascular injection Chloroprep or Alcohol swab(s) 4) Local Anesthetic Systemic Toxicity * (LAST) * LAST (local anesthetic systemic toxicity) 1) Rare and only with intravascular injection which an ultrasound guided approach prevents. 2) Signs include arrhythmias, seizures, convulsions 3) Treatment a.
    [Show full text]
  • Monitoring the Nociception Level Intraoperatively - an Initial Experiences
    Research Article J Anest & Inten Care Med Volume 7 Issue 2 - July 2018 Copyright © All rights are reserved by Pether Jildenstål DOI: 10.19080/JAICM.2018.07.555709 Monitoring the Nociception Level Intraoperatively - An Initial Experiences Pether Jildenstål1,2*, Katarina Hallén2, Katarina Almskog3, Johan Sand3 and Margareta Warren Stomberg1 1Institute of Health and Care Sciences, University of Gothenburg, Sweden 2Department of Anesthesiology, Surgery and Intensive Care, Sahlgrenska University Hospital, Sweden 3Department of Anesthesiology and Intensive care, Queen Silvia Children’s Hospital, Sweden Submission: July 5, 2018; Published: July 25, 2018 *Corresponding author: Pether Jildenstål, Institute of Health and Care Sciences, University of Gothenburg, Sweden, Email: Abstract Background: when vasopressors are used as well. There is an increasing interest during general anesthesia to understand how optimal anesthesia changes by Estimating pain stimuli in the anesthetized patient can be difficult when based solely upon physiological parameters, especially its exact use in routine clinical practice is still not well proven. The aim of this study was to identify relationships between PMD 200 monitoring, Nociceptionthe level of noxious Level (NOL-index) stimulation. and Objectively, monitored noxious known stimulation physiological measurement signs as well monitoring as outcomes techniques during general are gaining anesthesia. interest. Although currently, Method: during the intraoperativeEight patients period. between the ages of 43 and 83 years old and scheduled for major head and neck surgery under general anesthesia were observed in this study. NoL index sensor was placed on one of the patient’s fingers before anesthesia was induced, and values were extracted Results: of the bladder, and with surgical skin incision.
    [Show full text]
  • Herestraat 49, B-3000 Leuven Yves Kremer, CU Saint-Luc, Av
    Editor | Prof. Dr. V. Bonhomme CO-Editors | Dr. Y. Kremer — Prof. Dr. M. Van de Velde ACTA ANAESTHESIOLOGICA JOURNAL OF THE BELGIAN SOCIETY OF ANESTHESIOLOGY, RESUSCITATION, PERIOPERATIVE MEDICINE AND PAIN MANAGEMENT (BeSARPP) BELGICA Indexed in EMBASE l EXCERPTA MEDICA ISSN: 2736-5239 Suppl. 1 202071 Master Theses www.besarpp.be Cover-1 -71/suppl.indd 1 12/01/2021 12:37 ACTA ANÆSTHESIOLOGICA BELGICA 2020 – 71 – Supplement 1 EDITORS Editor-in-chief : Vincent Bonhomme, CHU Liège, av. de l’Hôpital 1, B-4000 Liège Co-Editors : Marc Van de Velde, KU Leuven, Herestraat 49, B-3000 Leuven Yves Kremer, CU Saint-Luc, av. Hippocrate, B-1200 Woluwe-Saint-Lambert Associate Editors : Margaretha Breebaart, UZA, Wilrijkstraat 10, B-2650 Edegem Christian Verborgh, UZ Brussel, Laarbeeklaan 101, B-1090 Jette Fernande Lois, CHU Liège, av. de l’Hôpital 1, B-4000 Liège Annelies Moerman, UZ Gent, C. Heymanslaan 10, B-9000 Gent Mona Monemi, CU Saint-Luc, av. Hippocrate, B-1200 Woluwe-Saint-Lambert Steffen Rex, KU Leuven, Herestraat 49, B-3000 Leuven Editorial assistant Carine Vauchel Dpt of Anesthesia & ICM, CHU Liège, B-4000 Liège Phone: 32-4 321 6470; Email: [email protected] Administration secretaries MediCongress Charlotte Schaek and Astrid Dedrie Noorwegenstraat 49, B-9940 Evergem Phone : +32 9 218 85 85 ; Email : [email protected] Subscription The annual subscription includes 4 issues and supplements (if any). 4 issues 1 issue (+supplements) Belgium 40€ 110€ Other Countries 50€ 150€ BeSARPP account number : BE97 0018 1614 5649 - Swift GEBABEBB Publicity : Luc Foubert, treasurer, OLV Ziekenhuis Aalst, Moorselbaan 164, B-9300 Aalst, phone: +32 53 72 44 61 ; Email : [email protected] Responsible Editor : Prof.
    [Show full text]
  • Update on the Management of Pain, Agitation, and Delirium in the ICU
    Update on the Management of Pain, Agitation, and Delirium in the ICU Kevin E. Anger, Pharm.D., BCPS Gilles Fraser, Pharm.D., MCCM Paul M. Szumita, Pharm.D., BCCCP, Manager Investigational Drug Clinical Pharmacist in Critical BCPS, FCCM Service Brigham and Women’s Care Clinical Pharmacy Practice Manager Hospital Maine Medical Center Brigham and Women’s Hospital Boston, Massachusetts Portland, Maine Boston, Massachusetts Disclosures • Faculty have nothing to disclose. Objectives • Describe recent literature on management of pain, agitation, and delirium (PAD) in the intensive care unit (ICU). • Apply key concepts in the selection of sedatives, analgesics, and antipsychotic agents in critically ill patients. • Recommend methods to overcome key barriers to optimizing pain, sedation, and delirium pharmacotherapy in critically ill patients. Case-Based Approach to Pain Management in the ICU Kevin E. Anger, Pharm.D., BCPS Manager Investigational Drug Service Brigham and Women’s Hospital Boston, Massachusetts Time for a Poll How to vote via the web or text messaging From any browser From a text message Pollev.com/ashp 22333 152964 How to vote via text message How to vote via the web Question #1 DT is a 70 yo male w/ COPD, S/P XRT for NSC lung CA, now admitted to the medical ICU for respiratory failure secondary to pneumonia meeting ARDS criteria. Significant home medications include oxycodone sustained release 40mg TID, oxycodone 10- 20mg Q4hrs PRN pain, Advair 500/50mcg BID, ASA 81mg QD, and albuterol neb Q4hrs PRN. DT is intubated is currently
    [Show full text]
  • Pharmacists' Roles on the Pain Management Team, Fall 2014
    Fall 2014, Volume 8, Issue 2 Canadian Pharmacy > Research > Health Policy > Practice > Better Health Pharmacists’ Roles on the Pain Management Team harmacists are an important resource for managing pain in their patients, in order to both optimize treatment and Pprevent the unintended consequences of potent analgesics. While the role of pharmacists in pain management was first addressed inthe Translator Summer 2012 edition1, this rapidly evolving area of pharmacy practice has generated a number of innovative models that highlight the unique role of the pharmacist. As Canadian pharmacists embrace expanded scopes of practice, there is an opportunity to specifically leverage their services to assist patients in managing their pain. This issue of the Translator highlights four different approaches to enhanced involvement of pharmacists in the management of chronic pain: n Pharmacist-led management of chronic pain: a randomized controlled exploratory trial from the UK n A pharmacist-initiated intervention trial in osteoarthritis n A pharmacist-led pain consultation for patients with concomitant substance use disorders n The impact of pharmacists in translating evidence to patients with low back pain 1 The Translator, Summer 2012, 6:3 Pharmacist-led management of chronic pain in primary care: results from a randomized controlled exploratory trial Bruhn H, Bond CM, Elliott AM, et al. Pharmacist-led management of chronic pain in primary care; results from a randomized controlled exploratory trial. BMJ Open 2013;3:e002361. Issue: In the UK, an estimated 80% of medication review of each patient’s medical chronic pain sufferers still report pain after Pharmacist prescribing and records, followed by a face-to-face consul- four years of follow-up.1 Most patients refer reviewing pain medication may tation.
    [Show full text]
  • Pain Management in People Who Have OUD; Acute Vs. Chronic Pain
    Pain Management in People Who Have OUD; Acute vs. Chronic Pain Developer: Stephen A. Wyatt, DO Medical Director, Addiction Medicine Carolinas HealthCare System Reviewer/Editor: Miriam Komaromy, MD, The ECHO Institute™ This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under contract number HHSH250201600015C. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government. Disclosures Stephen Wyatt has nothing to disclose Objectives • Understand the complexities of treating acute and chronic pain in patients with opioid use disorder (OUD). • Understand the various approaches to treating the OUD patient on an agonist medication for acute or chronic pain. • Understand how acute and chronic pain can be treated when the OUD patient is on an antagonist medication. Speaker Notes: The general Outline of the module is to first address the difficulties surrounding treating pain in the opioid dependent patient. Then to address the ways that patients with pain can be approached on either an agonist of antagonist opioid use disorder treatment. Pain and Substance Use Disorder • Potential for mutual mistrust: – Provider • drug seeking • dependency/intolerance • fear – Patient • lack of empathy • avoidance • fear Speaker Notes: It is the provider that needs to be well educated and skillful in working with this population. Through a better understanding of opioid use disorders as a disease, the prejudice surrounding the encounter with the patient may be reduced.
    [Show full text]